10-Q: Onconetix Faces Going Concern Amidst Merger & Debt Woes

Onconetix, Inc. reports substantial losses and a going concern warning, pivoting to a merger with Ocuvex Therapeutics while grappling with significant debt and product abandonment.

Summary

• Onconetix, Inc. reported a net loss of $10.9 million for the six months ended June 30, 2025, a significant improvement from $25.4 million in the same period of 2024.
• Revenue for the six months ended June 30, 2025, decreased substantially to $208,124 from $1.4 million in the prior year, primarily from Proteomedix product sales.
• The company had cash of approximately $0.3 million as of June 30, 2025, and approximately $0.2 million as of August 13, 2025, which is insufficient to fund operations for the next 12 months.
• A working capital deficit of approximately $11.8 million and an accumulated deficit of approximately $128.1 million were reported as of June 30, 2025.
• Onconetix has abandoned commercialization of its ENTADFI product and is in the process of destroying its inventory, having fully impaired the related assets in 2024.
• The company entered into a Merger Agreement with Ocuvex Therapeutics, Inc. on July 16, 2025, where pre-Closing Ocuvex stockholders are anticipated to own 90% of the combined company, and Onconetix stockholders 10%.
• Goodwill impairment losses totaled $11.5 million for the six months ended June 30, 2025, following a $15.5 million impairment in the same period of 2024.
• Multiple forbearance agreements and extensions have been granted for the $10 million in notes payable to Veru, Inc., with the latest maturity date extended to August 14, 2025, and one note's principal increased by $100,000 to $5.1 million.
• The company utilized an Equity Line of Credit (ELOC), receiving $6.4 million in proceeds by June 30, 2025, but management determined these funds are insufficient to sustain operations.
• A 1:85 reverse stock split was effected on June 13, 2025, following a 1:40 reverse stock split on September 24, 2024.

Sentiment

Score: 2

Explanation: The company is in severe financial distress, evidenced by a going concern warning, critically low cash, significant debt, and a highly dilutive merger. While net loss improved, revenue plummeted, and operational challenges persist, including material weaknesses in internal controls. The abandonment of a key product further underscores the negative outlook.

Positives

• Net loss significantly decreased to $10.9 million for the six months ended June 30, 2025, from $25.4 million in the prior year, indicating reduced operational losses.
• Net cash used in operating activities decreased to $3.4 million for the six months ended June 30, 2025, from $8.4 million in the prior year, showing improved cash burn efficiency.
• Selling, general, and administrative expenses decreased by $2.8 million for the six months ended June 30, 2025, due to cost-saving measures and reduced non-recurring professional fees.
• A gain on forgiveness of accounts payable of $0.9 million was recognized due to the settlement of IQVIA balances.
• The company secured an Equity Line of Credit (ELOC) for up to $25.0 million, having drawn $6.4 million by June 30, 2025, providing some capital infusion.

Negatives

• Revenue decreased significantly by 85.2% to $208,124 for the six months ended June 30, 2025, compared to $1.4 million in the prior year.
• The company has a substantial accumulated deficit of $128.1 million and a working capital deficit of $11.8 million as of June 30, 2025.
• Cash balance is critically low at approximately $0.3 million as of June 30, 2025, and $0.2 million as of August 13, 2025, insufficient to fund operations for the next 12 months.
• Significant debt obligations exist, including $8.7 million in notes payable due within 12 months, primarily to Veru, Inc.
• The company has abandoned commercialization of ENTADFI and is destroying inventory, indicating a failure in a previous strategic direction.
• Goodwill impairment losses of $11.5 million were recognized for the six months ended June 30, 2025, reflecting a decline in the fair value of acquired assets.
• The proposed merger with Ocuvex Therapeutics will result in significant dilution for current Onconetix stockholders, who are expected to own only 10% of the combined entity.
• The company has identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties, ineffective risk assessment, and insufficient accounting resources.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to significant operating losses, minimal revenue, and insufficient cash to fund operations for the next 12 months.
• Requirement for substantial additional capital in the short-term to fund operations, satisfy obligations, and commercialize Proclarix, with no assurance of availability on favorable terms.
• Significant debt owed to Veru, Inc. ($10 million principal, with one note's principal increased to $5.1 million), which the company may be unable to pay, potentially leading to legal action or bankruptcy.
• High current liabilities of approximately $12.7 million, which could lead to creditors demanding immediate payment, resulting in bankruptcy and no distribution to stockholders.
• Uncertainty regarding the completion of the Ocuvex merger, which is subject to various conditions including stockholder approvals and debt restructuring, and could cause business disruptions and employee retention issues.
• Potential for significant transaction costs related to the merger, which will be incurred regardless of whether the merger is completed.
• Risk of market price decline for the combined company's common stock post-merger if investors react negatively or expected benefits are not realized.
• Dilution of existing Onconetix stockholders' ownership interests due to the merger and potential future equity issuances.
• Restrictions in the Merger Agreement that may prevent Onconetix from pursuing other attractive business opportunities or alternative transactions.
• Litigation risk related to the merger, which could incur significant costs and divert management attention.
• If the merger is not completed, the Onconetix Board may pursue dissolution and liquidation, potentially leaving little or no cash for distribution to stockholders after satisfying obligations.
• Reliance on third parties (e.g., LabCorp) for development, marketing, distribution, and sales of Proclarix, and on single-source suppliers for manufacturing, posing dependency risks.
• Inability to predict the timing or cost of completing clinical programs for future product candidates or regulatory approvals.
• Exposure to product liability lawsuits, which could limit commercialization efforts.
• Material weaknesses in internal control over financial reporting, including inadequate segregation of duties, ineffective risk assessment, and insufficient accounting resources, which could lead to undetected material misstatements.

Future Outlook

The company anticipates continuing to incur significant operating losses for the foreseeable future and will require substantial additional capital to fund operations, satisfy existing obligations, and commercialize Proclarix. Management plans to generate product revenue from Proclarix sales by 2027 and secure additional funding through equity or debt financings, including utilizing the ELOC. However, current ELOC availability is deemed insufficient to sustain operations, and there are no other committed financing sources. The proposed merger with Ocuvex Therapeutics is expected to result in Ocuvex stockholders owning 90% of the combined entity, subject to various closing conditions including Onconetix's debt restructuring. The company expects expenses to increase substantially with Proclarix commercialization and public company operations.

Management Comments

• Our current cash balance is not sufficient to fund its operations through twelve months after the date these financials are issued, unless it can obtain other financing or utilize the Equity Financing Line of Credit (ELOC).
• Projections are indicative that it will be unable to meet its contractual commitments and obligations as they come due in the ordinary course of business.
• Management determined that the funds readily available under the ELOC will not be sufficient to sustain operations.
• There are currently no other commitments in place for further financing nor is there any assurance that such financing will be available to the Company on favorable terms, if at all.
• If the Company is unable to secure additional capital, it may be required to curtail any future clinical trials, development and/or commercialization of future product candidates, and it may take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations, or, if it is required to, file for bankruptcy.
• Because of historical and expected operating losses, net operating cash flow deficits, and debts due within one year, there is substantial doubt about the Companys ability to continue as a going concern for one year from the issuance of the consolidated financial statements, which is not alleviated by managements plans.

Industry Context

Onconetix operates in the commercial-stage biotechnology sector, specifically focusing on men's health and oncology diagnostics with its Proclarix product. The abandonment of ENTADFI highlights the high-risk nature and capital intensity of drug commercialization, especially for smaller biotech firms. The strategic pivot to focus solely on Proclarix and the proposed merger with Ocuvex Therapeutics reflect a common trend in the biotech industry where companies with limited cash runway seek consolidation or a new strategic direction to survive and advance their pipelines. The reliance on a diagnostic product like Proclarix, which is CE-marked in the EU and licensed to LabCorp in the US, positions the company in a competitive diagnostic market, where successful commercialization and market penetration are critical for financial viability.

Comparison to Industry Standards

• Onconetix's financial position, characterized by a significant accumulated deficit ($128.1 million) and a going concern warning, is typical of early-stage biotechnology companies that incur substantial R&D and commercialization costs before generating significant revenue. However, the current cash balance of $0.2 million and working capital deficit of $11.8 million are critically low, placing the company in a more precarious position than many peers who typically maintain longer cash runways.
• The abandonment of ENTADFI, an FDA-approved product, due to 'time and resources needed' and 'cash runway and indebtedness' is a notable negative outlier, as most biotech companies strive to commercialize approved assets. This suggests significant operational or market challenges beyond typical commercialization hurdles.
• The proposed merger with Ocuvex, where existing Onconetix shareholders will retain only 10% of the combined entity, indicates a distressed valuation for Onconetix, often seen in 'reverse merger' scenarios where a struggling public company is acquired by a private entity to gain public market access. This level of dilution is severe compared to typical strategic mergers among financially stable companies.
• The repeated extensions and modifications of debt agreements with Veru, Inc., including an increase in principal, are indicative of severe financial strain and an inability to meet obligations, which is a red flag compared to companies with healthier balance sheets that can service their debt without constant renegotiation.
• The identified material weaknesses in internal control over financial reporting, such as inadequate segregation of duties and insufficient accounting resources, are below industry best practices for publicly traded companies and raise concerns about financial integrity and operational efficiency.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened claims as of June 30, 2025.

Related Party Transactions

• On December 18, 2023, the company entered into a Subscription Agreement with the PMX Investor, a 5% stockholder of the company as of June 30, 2025.
• During 2024, the company issued a non-convertible debenture in the principal amount of $5.0 million to the PMX Investor, which was later settled through the issuance of shares.
• On February 6, 2024, Thomas Meier, PhD, was appointed to the Board of Directors and provides consulting services to Proteomedix through a consulting agreement effective January 4, 2024.
• On June 17, 2025, the company entered into a separate consulting agreement with a firm affiliated with Dr. Meier, entitling him to 10% of success fees earned by the firm.

Stakeholder Impact

• **Shareholders:** Face significant dilution from the proposed Ocuvex merger (expected to own 10% of combined entity) and potential future equity raises. Risk of losing all or significant portion of investment if the company liquidates due to going concern issues. Existing common stock value is highly speculative.
• **Employees:** Cost reduction efforts, including headcount reductions, have occurred. Uncertainty surrounding the merger and financial stability may impact employee morale and retention.
• **Creditors (especially Veru, Inc.):** The company owes significant amounts to Veru, Inc. ($10 million principal, with one note increased to $5.1 million), and has repeatedly sought forbearance and extensions, indicating high risk of default. Other vendors also face payment risk due to high current liabilities.
• **Customers (e.g., LabCorp):** Commercialization of Proclarix is ongoing, but LabCorp's US commercialization has not commenced. The abandonment of ENTADFI could impact customer confidence in the company's product pipeline and long-term viability.
• **Suppliers:** The company relies on single-source suppliers for Proclarix manufacturing, which could be impacted by the company's financial instability or changes in strategic direction.

Next Steps

• Solicit a sufficient number of proxies to approve the merger with Ocuvex Therapeutics and other related matters.
• Satisfy or waive customary conditions for the Ocuvex merger, including stockholder approvals, Nasdaq listing, and registration statement effectiveness.
• Restructure certain outstanding indebtedness of the company as a condition for Ocuvex to complete the merger.
• File a registration statement on Form S-4 with the SEC, including a preliminary proxy statement and prospectus for the proposed merger.
• Continue commercialization activities for Proclarix, with revenue expected by 2027.
• Secure additional required funding through equity or debt financings beyond the current ELOC.
• Implement remediation plans for identified material weaknesses in internal control over financial reporting, including improving segregation of duties, risk assessment, and IT controls.

Key Dates

Recommendation

Onconetix faces an immediate and severe going concern risk, with critically low cash reserves insufficient to cover operations for the next year. The proposed merger with Ocuvex, while a potential lifeline, comes at an extreme cost to existing shareholders, who will be diluted to a mere 10% ownership. The abandonment of an FDA-approved product (ENTADFI) and persistent debt issues, including repeated forbearance agreements with a key creditor (Veru), highlight profound financial distress and operational mismanagement. Furthermore, identified material weaknesses in internal controls raise governance concerns. Given the high probability of further dilution, potential bankruptcy, and a highly uncertain path to profitability, the stock represents an exceptionally high-risk investment with significant downside.

Keywords

Biotechnology, Prostate Cancer, Diagnostics, Proclarix, SEC Filing, 10-Q, Going Concern, Merger, Ocuvex Therapeutics, Debt, Liquidity, Financial Reporting, SEC, Biotech, Healthcare